Antiretroviral therapy does not affect response to chronic hepatitis C therapy in HIV-coinfected patients.

Introduction: Many patients coinfected with the human immunodeficiency virus (HIV) and hepatitis C virus (HCV) are using highly active antiretroviral therapy (HAART) and HCV therapy with peginterferon (PEG-IFN) and ribavirina (RBV) because the use of direct-acting antivirals is not a reality in some countries. To know the impact of such medications in the sustained virological response (SVR) during HCV treatment is of great importance.

Methodology: This was a retrospective cohort study of 215 coinfected HIV/HCV patients.